Key Y. Shin works closely with life sciences companies, at all stages of development, variously engaged in developing drugs, medical devices, diagnostics, and digital health technologies. He helps clients structure and complete critical transactions, from in-licensing patents that form the foundation of the companies’ patent estate, through services arrangements with CMOs, CROs, and other development partners, and eventually commercial partnering of the program, sale of the company, or other exit transaction.
Key has experience structuring joint development arrangements between collaborators coming from both similar and widely disparate core technological competencies, often involving complex IP allocation issues. Key assists companies in establishing long term research collaborations with universities that go beyond typical sponsored research and technical services agreements. Key also works with research accelerators working in innovative ways to facilitate collaborative research among investigators from different research institutions worldwide, successfully navigating the conflicting IP, publication, and liability positions of participating institutions.
Prior to joining Morgan Lewis, Key was of counsel at another international law firm. He also previously served as the associate general counsel for Nuvelo, Inc., and practiced technology transactions and corporate commercial law at a national firm in Canada.
Collaborations and Licenses
Patent license from a university for digital health data applications developer.
Research collaborations with wearable technology companies to facilitate discovery of diagnostics and therapeutics in neurologic indications.
Antares Pharma, Inc. in its agreement with Idorsia Pharmaceuticals for the development of a novel drug device combination product to be developed for the treatment of suspected acute myocardial Infarction.
Dewpoint Therapeutics in its option, research and license agreement valued up to $100 million that will leverage Dewpoint’s proprietary platform for biomolecular condensates and Bayer’s small molecule compound library to develop new treatments for cardiovascular and gynecological diseases.
Celgene Corporation in its amended collaboration agreement with Editas Medicine, Inc. which allows the parties to research, develop, and commercialize autologous and allogeneic alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases, and enables Editas Medicine to receive an upfront payment of $70 million as well as potential future milestones and royalty payments.
Gilead Sciences in its research and development collaboration valued up to $475 million with Carna Biosciences Inc. to develop and commercialize small molecule compounds in immuno-oncology and to access Carna's proprietary lipid kinase drug discovery platform.
Antares Pharma, Inc. in its agreement with Pfizer to develop a combination drug device overdose rescue pen under which Pfizer will develop and commercialize the product in the US and Antares will receive royalties on net sales.
Natera in its agreement with Qiagen to develop cell-free DNA assays for use on Qiagen’s GeneReader NGS System for prenatal screening.
Talee Bio, a gene therapy company developing the next generation treatment and cures for cystic fibrosis, in its sale to Roivant Sciences.
CrystalGenomics in a license, development, and commercialization agreement on cancer therapeutic lead with Aptose, Inc.
Novadaq Technologies Inc. in a multi-year license and development agreement with Intuitive Surgical Inc. to integrate Novadaq’s SPY fluorescence imaging technology into the 3D high definition imaging capabilities of Intuitive’s da Vinci® Surgical Robot Systems.Strata Pharmaceuticals, Inc., in a collaboration and license agreement with Micrologix Biotech Inc. to develop and commercialize MBI-226, a topical cationic antimicrobial peptide in Phase III clinical development for the treatment of catheter-related infections.
Dynavax Technologies Corporation in a strategic partnering agreement with UCB Pharma to out-license ragweed and grass allergy immunotherapy programs with an option for the peanut allergy program.
Neurosystec Corporation in a development and license agreement with DURECT Corporation to develop and commercialize compounds for the treatment of tinnitus and to improve postoperative recovery and tolerance of cochlear implants.
MediGene, Inc., in a license agreement with the University of Chicago for targeting methodology to increase the efficiency of MediGene’s oncolytic herpes simplex virus therapy under phase I/II development.
Dynavax Technologies Corporation in license and services agreements to form its Singapore-based subsidiary, Dynavax Asia.
Chiron Corporation (now part of Novartis) in a license agreement with Cubist Pharmaceuticals, Inc., to develop and commercialize Cubicin® (Daptomycin for injection), an antibiotic approved for treatment of complicated skin and skin structure infections caused by gram-positive bacteria, in Europe, Australia, New Zealand, India, and certain Central American, South American, and Middle Eastern countries.
Bradley Pharmaceuticals, Inc., in a license agreement with BioSante Pharmaceuticals for United States marketing rights for Bio-E-Gel transdermal gel estradiol.
NovaRx Corporation in a transaction with Immune Response Corporation to transfer all of the latter’s development and marketing rights to cancer cell line vaccines in-licensed from the Sidney Kimmel Cancer Center.
Nuvelo, Inc. (formerly Hyseq Pharmaceuticals, Inc.) in a collaboration with Amgen Inc. to develop and commercialize Alfimeprase, a novel acting thrombolytic, for the treatment of peripheral arterial occlusion and other cardiovascular indications.
Saegis Pharmaceuticals, Inc., in a license and development arrangement with Eli Lilly and Company for the clinical development of a compound for the enhancement of cognition.
InSite Vision Incorporated in a collaboration with Bausch & Lomb Inc. for the development and commercialization of a fourth-generation fluoroquinolone combined with InSite Vision’s proprietary ophthalmic drug delivery technology.
InSite Vision Incorporated in its distribution license with SIFI (Societa Industria Farmaceutica Italiana) S.p.A. for the manufacturing and distribution of InSite Visions’s OcuGene® genetic test for glaucoma in Italy.
Genelabs Technologies, Inc., in a cross-license arrangement with the University of Iowa Research Foundation to study the impact of the Hepatitis G virus (HGV, also known as GB virus C or GBV-C) on human immunodeficiency virus (HIV) infection.
CrystalGenomics in a multi-year research collaboration on therapeutic leads with AstraZeneca plc.
Konica Minolta in a comprehensive business partnership and capital investment agreement with Konarka Technologies Inc. for the development and distribution of organic thin-film photovoltaics. Konica Minolta invested US $20 million in Konarka as part of the joint development agreement to start full-scale collaboration.
Effector Cell Institute, Inc. in its collaborative research agreement with AstraZeneca plc.
M&A and Financings
Inamed Corporation in its $3.4 billion acquisition by Allergan, Inc.
Applied Biosystems, Inc., in its $120 million acquisition of Agencourt Personal Genomics, a developer of next generation genetic analysis technologies.
Oculex Pharmaceuticals, Inc., a developer of innovative therapies for sight-threatening diseases, in its $230 million acquisition by Allergan, Inc. Oculex’s lead product Posurdex® showed promising Phase II results for macula edema.
Applied Biosystems, Inc., in its acquisition of Ambion, Inc., and subsequent spinout of the diagnostics and services business.
Novadaq Corp. in its acquisition of exclusive United State distribution rights for PLC Medical System Inc.’s HEART LASERTM SYSTEM for transmyocardial revascularization (TMR) from Edwards Lifesciences.
Jennerex Biotherapeutics, Inc., a novel cancer therapeutic company in its Series A financing.
Pequot Capital Management, Inc., in its lead of the $10.8 million Series B financing of NuGen Technologies, Inc., developer of single primer isothermal nucleic acid amplification and analysis technologies.
Lehman Brothers Healthcare Venture Partners in its lead of the $34 million Series C financing of Fluidigm, Inc., developer of microfluidics “lab on a chip” technologies.
NeuroVentures Capital LLC in its financing of Kadmus Pharmaceuticals, Inc., for development and commercialization of proprietary molecules that target critical pathways contributing to pain and other disorders of the nervous system.
Ash Stevens, Inc. in commercial supply agreement with Pharmion Inc. (now Celgene) for API for Vidaza.
Chiron Corporation (now part of Novartis) in commercial manufacturing and supply agreement with Cubist Pharmaceuticals, Inc. for Cubicin (Daptomycin for injection).
Santarus, Inc. in commercial manufacturing agreements with UQUIFA for API supply and Patheon for fill & finish services.
Technology Licenses and Clinical Trial Agreements
Key has represented clients in negotiating licenses of IP, sponsored research agreements and clinical trial agreements opposite numerous universities and research institutions including:
Brigham and Women’s Hospital
City of Hope
MD Anderson Cancer Center
Memorial Sloan-Kettering Cancer Center
National Institutes of Health
Ottawa Health Research Institute
Simon Fraser University
The Broad Institute
Thomas Jefferson University
University of British Columbia
University of California
University of Chicago
University of Louisville
University of Maryland (Baltimore)
University of Massachusetts
University of Minnesota
University of Pennsylvania
University of Washington
University of Victoria, British Columbia, 1991, J.D.